High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival. Systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. This short overview summarizes the results of the combination with regional hyperthermia as a new treatment strategy to open a new therapeutic window.
Issels
Rolf D
RD
University Hospital Medical Center Grosshadern, Medical Clinic III, LMU Munich and KKG Hyperthermie, GSF, National Research Center for Environment and Health, Munich, Germany. rolf.issels@med.uni-muenchen.de
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D012509:Sarcoma / Q000188:drug therapy / Q000628:therapy*; D016019:Survival Analysis